206 related articles for article (PubMed ID: 11161468)
1. Mutant huntingtin enhances excitotoxic cell death.
Zeron MM; Chen N; Moshaver A; Lee AT; Wellington CL; Hayden MR; Raymond LA
Mol Cell Neurosci; 2001 Jan; 17(1):41-53. PubMed ID: 11161468
[TBL] [Abstract][Full Text] [Related]
2. Protective up-regulation of CK2 by mutant huntingtin in cells co-expressing NMDA receptors.
Fan MM; Zhang H; Hayden MR; Pelech SL; Raymond LA
J Neurochem; 2008 Feb; 104(3):790-805. PubMed ID: 17971125
[TBL] [Abstract][Full Text] [Related]
3. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
4. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
[TBL] [Abstract][Full Text] [Related]
6. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease.
Li L; Fan M; Icton CD; Chen N; Leavitt BR; Hayden MR; Murphy TH; Raymond LA
Neurobiol Aging; 2003 Dec; 24(8):1113-21. PubMed ID: 14643383
[TBL] [Abstract][Full Text] [Related]
7. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease.
Zeron MM; Hansson O; Chen N; Wellington CL; Leavitt BR; Brundin P; Hayden MR; Raymond LA
Neuron; 2002 Mar; 33(6):849-60. PubMed ID: 11906693
[TBL] [Abstract][Full Text] [Related]
8. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
9. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease.
Li L; Murphy TH; Hayden MR; Raymond LA
J Neurophysiol; 2004 Nov; 92(5):2738-46. PubMed ID: 15240759
[TBL] [Abstract][Full Text] [Related]
10. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
11. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
12. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin.
Chen N; Luo T; Wellington C; Metzler M; McCutcheon K; Hayden MR; Raymond LA
J Neurochem; 1999 May; 72(5):1890-8. PubMed ID: 10217265
[TBL] [Abstract][Full Text] [Related]
13. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
[TBL] [Abstract][Full Text] [Related]
14. Hunting for excitement: NMDA receptors in Huntington's disease.
Ellerby LM
Neuron; 2002 Mar; 33(6):841-2. PubMed ID: 11906690
[TBL] [Abstract][Full Text] [Related]
15. PGC-1α negatively regulates extrasynaptic NMDAR activity and excitotoxicity.
Puddifoot C; Martel MA; Soriano FX; Camacho A; Vidal-Puig A; Wyllie DJ; Hardingham GE
J Neurosci; 2012 May; 32(20):6995-7000. PubMed ID: 22593067
[TBL] [Abstract][Full Text] [Related]
16. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
17. Altered NMDA receptor trafficking in a yeast artificial chromosome transgenic mouse model of Huntington's disease.
Fan MM; Fernandes HB; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2007 Apr; 27(14):3768-79. PubMed ID: 17409241
[TBL] [Abstract][Full Text] [Related]
18. Mutant huntingtin promotes the fibrillogenesis of wild-type huntingtin: a potential mechanism for loss of huntingtin function in Huntington's disease.
Busch A; Engemann S; Lurz R; Okazawa H; Lehrach H; Wanker EE
J Biol Chem; 2003 Oct; 278(42):41452-61. PubMed ID: 12888569
[TBL] [Abstract][Full Text] [Related]
19. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
Graham RK; Deng Y; Slow EJ; Haigh B; Bissada N; Lu G; Pearson J; Shehadeh J; Bertram L; Murphy Z; Warby SC; Doty CN; Roy S; Wellington CL; Leavitt BR; Raymond LA; Nicholson DW; Hayden MR
Cell; 2006 Jun; 125(6):1179-91. PubMed ID: 16777606
[TBL] [Abstract][Full Text] [Related]
20. CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content.
Boussicault L; Kacher R; Lamazière A; Vanhoutte P; Caboche J; Betuing S; Potier MC
Biochimie; 2018 Oct; 153():70-79. PubMed ID: 30107216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
